Marc Scherlinger, Gaetane Nocturne, Marko Radic, David Launay, Christophe Richez, Philippe Bousso, Edouard Forcade, Alain Meyer, Christian Jorgensen, Camille Bigenwald, Divi Cornec, Jean Sibilia, Sylvain Choquet, Thierry Martin, Alexandre Belot, Maurine Jouret, Samuel Bitoun, Zahir Amoura, Olivier Hermine, Xavier Mariette, Emmanuel Donnadieu, Jérome Avouac
{"title":"自体免疫疾病中的CAR - t细胞疗法：我们在哪里，我们将走向何方？","authors":"Marc Scherlinger, Gaetane Nocturne, Marko Radic, David Launay, Christophe Richez, Philippe Bousso, Edouard Forcade, Alain Meyer, Christian Jorgensen, Camille Bigenwald, Divi Cornec, Jean Sibilia, Sylvain Choquet, Thierry Martin, Alexandre Belot, Maurine Jouret, Samuel Bitoun, Zahir Amoura, Olivier Hermine, Xavier Mariette, Emmanuel Donnadieu, Jérome Avouac","doi":"10.1016/S2665-9913(24)00377-1","DOIUrl":null,"url":null,"abstract":"<p><p>Chimeric antigen receptor (CAR)-based therapies developed for the treatment of haematological malignancies have recently been repurposed to treat refractory systemic autoimmune diseases. In this Review we critically discuss the current data available on the use of CAR-based therapy in systemic autoimmune diseases, the current challenges, and the potential next steps toward their implementation into clinical practice. Beyond the targeting of B cells via CD19, we discuss the advantages and potential pitfalls of targeting plasma cells (B-cell Maturation Antigen or CD138) and other non-immune targets, such as fibroblast activated protein, and of aiming to restore immune homeostasis using CAR T regulatory cells. Crucial points need to be addressed for CAR-based therapy to become a viable treatment option for patients with systemic autoimmune diseases.</p>","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":" ","pages":""},"PeriodicalIF":15.0000,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CAR T-cell therapy in autoimmune diseases: where are we and where are we going?\",\"authors\":\"Marc Scherlinger, Gaetane Nocturne, Marko Radic, David Launay, Christophe Richez, Philippe Bousso, Edouard Forcade, Alain Meyer, Christian Jorgensen, Camille Bigenwald, Divi Cornec, Jean Sibilia, Sylvain Choquet, Thierry Martin, Alexandre Belot, Maurine Jouret, Samuel Bitoun, Zahir Amoura, Olivier Hermine, Xavier Mariette, Emmanuel Donnadieu, Jérome Avouac\",\"doi\":\"10.1016/S2665-9913(24)00377-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Chimeric antigen receptor (CAR)-based therapies developed for the treatment of haematological malignancies have recently been repurposed to treat refractory systemic autoimmune diseases. In this Review we critically discuss the current data available on the use of CAR-based therapy in systemic autoimmune diseases, the current challenges, and the potential next steps toward their implementation into clinical practice. Beyond the targeting of B cells via CD19, we discuss the advantages and potential pitfalls of targeting plasma cells (B-cell Maturation Antigen or CD138) and other non-immune targets, such as fibroblast activated protein, and of aiming to restore immune homeostasis using CAR T regulatory cells. Crucial points need to be addressed for CAR-based therapy to become a viable treatment option for patients with systemic autoimmune diseases.</p>\",\"PeriodicalId\":48540,\"journal\":{\"name\":\"Lancet Rheumatology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":15.0000,\"publicationDate\":\"2025-03-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lancet Rheumatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/S2665-9913(24)00377-1\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/S2665-9913(24)00377-1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?
Chimeric antigen receptor (CAR)-based therapies developed for the treatment of haematological malignancies have recently been repurposed to treat refractory systemic autoimmune diseases. In this Review we critically discuss the current data available on the use of CAR-based therapy in systemic autoimmune diseases, the current challenges, and the potential next steps toward their implementation into clinical practice. Beyond the targeting of B cells via CD19, we discuss the advantages and potential pitfalls of targeting plasma cells (B-cell Maturation Antigen or CD138) and other non-immune targets, such as fibroblast activated protein, and of aiming to restore immune homeostasis using CAR T regulatory cells. Crucial points need to be addressed for CAR-based therapy to become a viable treatment option for patients with systemic autoimmune diseases.
期刊介绍：
The Lancet Rheumatology, an independent journal, is dedicated to publishing content relevant to rheumatology specialists worldwide. It focuses on studies that advance clinical practice, challenge existing norms, and advocate for changes in health policy. The journal covers clinical research, particularly clinical trials, expert reviews, and thought-provoking commentary on the diagnosis, classification, management, and prevention of rheumatic diseases, including arthritis, musculoskeletal disorders, connective tissue diseases, and immune system disorders. Additionally, it publishes high-quality translational studies supported by robust clinical data, prioritizing those that identify potential new therapeutic targets, advance precision medicine efforts, or directly contribute to future clinical trials.
With its strong clinical orientation, The Lancet Rheumatology serves as an independent voice for the rheumatology community, advocating strongly for the enhancement of patients' lives affected by rheumatic diseases worldwide.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
